IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.766
EU - Europa 8.637
AS - Asia 7.889
SA - Sud America 2.326
Continente sconosciuto - Info sul continente non disponibili 535
AF - Africa 183
OC - Oceania 12
AN - Antartide 1
Totale 28.349
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.220
RU - Federazione Russa 4.477
SG - Singapore 2.687
CN - Cina 2.341
BR - Brasile 1.895
IT - Italia 1.435
HK - Hong Kong 1.060
VN - Vietnam 849
SE - Svezia 784
RO - Romania 559
FR - Francia 390
BD - Bangladesh 324
DE - Germania 273
CA - Canada 228
GB - Regno Unito 200
AR - Argentina 169
IN - India 145
FI - Finlandia 118
MX - Messico 102
ID - Indonesia 86
EC - Ecuador 75
ZA - Sudafrica 70
NL - Olanda 65
AT - Austria 64
CO - Colombia 59
PL - Polonia 56
ES - Italia 55
JP - Giappone 50
TR - Turchia 48
IQ - Iraq 46
CR - Costa Rica 41
VE - Venezuela 34
IE - Irlanda 32
UA - Ucraina 32
JM - Giamaica 29
PK - Pakistan 28
CL - Cile 27
MA - Marocco 26
PY - Paraguay 26
UZ - Uzbekistan 25
HN - Honduras 23
EG - Egitto 22
NI - Nicaragua 21
MY - Malesia 20
IR - Iran 19
PR - Porto Rico 19
UY - Uruguay 19
AE - Emirati Arabi Uniti 18
LT - Lituania 18
SA - Arabia Saudita 18
KE - Kenya 17
TT - Trinidad e Tobago 17
GT - Guatemala 16
NP - Nepal 16
PE - Perù 15
TN - Tunisia 14
AL - Albania 13
PH - Filippine 13
TH - Thailandia 13
AU - Australia 12
DZ - Algeria 11
IL - Israele 11
JO - Giordania 11
AZ - Azerbaigian 10
MD - Moldavia 10
EU - Europa 9
SV - El Salvador 9
BB - Barbados 8
BY - Bielorussia 8
CW - ???statistics.table.value.countryCode.CW??? 8
OM - Oman 8
AO - Angola 7
BE - Belgio 7
BO - Bolivia 6
EE - Estonia 6
KZ - Kazakistan 6
LB - Libano 6
PT - Portogallo 6
PA - Panama 5
BM - Bermuda 4
CH - Svizzera 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
PS - Palestinian Territory 4
TW - Taiwan 4
XK - ???statistics.table.value.countryCode.XK??? 4
CZ - Repubblica Ceca 3
ET - Etiopia 3
GA - Gabon 3
GD - Grenada 3
GP - Guadalupe 3
HR - Croazia 3
HT - Haiti 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
KY - Cayman, isole 3
SC - Seychelles 3
SN - Senegal 3
A1 - Anonimo 2
Totale 27.794
Salva come PNG Salva come JPEG
Città #
Dallas 1.297
Singapore 1.242
Ashburn 1.105
Moscow 1.062
Hong Kong 1.051
San Jose 836
Council Bluffs 526
Shanghai 403
Hefei 368
Ho Chi Minh City 339
Beijing 338
Milan 333
Lauterbourg 321
Princeton 317
Lawrence 314
New York 306
Los Angeles 198
Santa Clara 184
São Paulo 172
Hanoi 157
Rome 119
Phoenix 107
Helsinki 95
Chicago 80
North Bergen 79
Boardman 74
Miano 74
Nuremberg 69
Munich 67
Orem 65
Rio de Janeiro 60
Atlanta 51
Warsaw 49
Brooklyn 47
Guangzhou 46
Haiphong 44
Montreal 44
Naples 42
Tokyo 42
Toronto 42
Omaha 40
Houston 39
Denver 37
Belo Horizonte 36
Boston 35
Chennai 35
Stockholm 35
Brasília 34
London 33
Cesano Boscone 32
Da Nang 32
Mexico City 32
Poplar 32
San José 31
Vienna 31
Dublin 30
Johannesburg 30
Buffalo 29
Porto Alegre 28
Guayaquil 27
The Dalles 26
Campinas 24
Curitiba 24
Frankfurt am Main 24
Manchester 24
Tashkent 24
Kingston 23
Quito 23
Amsterdam 22
Columbus 22
Ankara 21
Bologna 21
Dhaka 21
Guarulhos 21
Mumbai 21
Palermo 21
Ribeirão Preto 21
San Francisco 21
Tianjin 20
Washington 20
Biên Hòa 19
Thái Bình 19
Turin 19
Brescia 18
Las Vegas 18
Managua 18
Baghdad 17
Buenos Aires 16
Cape Town 16
Genoa 16
Montevideo 16
Salvador 16
Seattle 16
Charlotte 15
Cleveland 15
Florence 15
Hortolândia 15
Jacksonville 15
Philadelphia 15
Shenzhen 15
Totale 13.596
Salva come PNG Salva come JPEG
Nome #
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 484
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 446
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 438
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 363
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 251
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 176
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 169
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 167
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 150
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 146
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 144
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 142
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 142
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 138
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 135
The evolving role of microsatellite instability in colorectal cancer: A review 134
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 133
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 133
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 133
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 132
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 129
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 127
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 127
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 126
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 125
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 125
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 123
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 123
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 122
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 121
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 119
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 119
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 119
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 119
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 118
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 118
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 117
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 117
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 116
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 116
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 115
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 114
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 114
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 113
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 112
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 112
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 111
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 110
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 109
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 109
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 108
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 108
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 107
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 106
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 106
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 106
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 105
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 104
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 104
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 103
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 103
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 102
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 102
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 102
5-Fluorouracil pharmacogenomics: still rocking after all these years? 101
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 100
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 100
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 99
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 99
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 98
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 97
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 97
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 96
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 96
Cholangiocarcinoma: new perspectives for new horizons 95
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 94
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 94
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 94
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 93
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 93
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 93
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 92
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 91
Evaluation of prognostic factors for survival in transverse colon cancer 91
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 91
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 90
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 90
BRAF-mutated colorectal cancer: Clinical and molecular insights 89
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 88
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 88
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi 87
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 87
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 85
Cetuximab: still an option in the treatment of pancreatic cancer? 85
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 85
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 85
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 84
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 83
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 82
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 82
Totale 12.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 170.412
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 170.412
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022228 0 0 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.209 624 116 62 58 94 428 1.068 459 831 774 304 391
2025/202616.121 1.098 1.505 1.452 2.200 1.126 540 1.179 1.079 4.012 675 570 685
2026/20274.311 722 1.015 962 1.612 0 0 0 0 0 0 0 0
Totale 28.349